← All trials
NCT06427590
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 13, 2024
- Primary completion
- Dec 31, 2024
- Completion date
- Apr 30, 2025
- First posted
- May 24, 2024
- Last posted
- Sep 19, 2024
- Enrollment
- 36
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ascletis Pharmaceuticals Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.